Pharma major, Cipla Limited, informed the bourses on Thursday that it was commercialising antibody detection kits for COVID-19 in India under the technology transfer from Indian Council of Medical Research (ICMR) in partnership with Karwa Limited.
As a part of this collaboration, the company would be responsible for the marketing and distribution of the SARS CoV-2-IgG antibody detector that will be manufactured by Karwa Ltd and marketed under the brand name, ELIFast.
In an exchange filing, the company informed that Cipla’s extensive distribution network will ensure a seamless supply of kits across the country through the channels approved by ICMR in order to ensure equitable access.
Besides, the company also added that the product has been validated by ICMR and National Institute of Virology (NIV), and is found to have specificity & sensitivity of 99.33 per cent and 92 per cent, respectively.
On Thursday, the stock of Cipla Limited closed at Rs 763 per share, down by 0.28 per cent or Rs 2.15 per share on BSE, against a 0.43 per cent decline in the benchmark index. Its 52-week high is recorded at Rs 829 and the 52-week low is Rs 356.75 on BSE.